OmniAsset
Get app

OmniAsset › Mutual funds › Nippon India Nifty Pharma ETF

Nippon India Nifty Pharma ETF

ETF fund benchmarked to Nifty Pharma TRI. Every figure below is read from one dated snapshot; what the snapshot cannot prove is left out, never estimated.

Latest NAV2 Sep 202627.5413
CategoryETF
PlanDirect
Launched21 Jun 2021
Risk labelthe scheme's own riskometerVery High
Legal benchmarkSEBI Tier-1Nifty Pharma TRI
Expense ratiodirect plan, a year · stated maximum, from the scheme document0.24%
AUM₹1,458 Cr
Growth of ₹10,000₹18,9802 Sep 2021 to 2 Sep 2026
₹19,268₹16,473₹13,678₹10,883₹8,088Sep 2021Nov 2022Mar 2024Jun 2025Sep 2026
₹18,980 (+13.7% a year) Nippon India Nifty Pharma ETF

Performance (trailing, annualised)

1Y annualised23.76%
3Y annualised21.75%
5Y annualised13.68%

Point-to-point from the fund's own published NAV; a period the history does not span is left out.

SIP returns

SIP 1Y (₹10,000 a month)invested ₹1,20,000 → worth ₹1,39,99932.16%
SIP 3Y (₹10,000 a month)invested ₹3,60,000 → worth ₹4,71,83818.37%
SIP 5Y (₹10,000 a month)invested ₹6,00,000 → worth ₹9,70,44219.31%

₹10,000 on the first of every month, valued at the latest NAV, as an annualised rate (XIRR).

Calendar years

Calendar 2022-10.86%
Calendar 202334.44%
Calendar 202439.59%
Calendar 2025-2.46%

Rolling returns

Rolling 1Y · average215 windows since 6 Jul 202216.36%
Rolling 1Y · median12.55%
Rolling 1Y · worst window-13.97%
Rolling 1Y · best window62.78%
Rolling 1Y · windows positive73%
Rolling 3Y · average111 windows since 11 Jul 202420.17%
Rolling 3Y · median20.19%
Rolling 3Y · worst window12.99%
Rolling 3Y · best window27.05%
Rolling 3Y · windows positive100%

Every window of that length in the published history, so one lucky start date cannot flatter the fund.

Risk

Volatility (3Y)15.09%
Downside deviation (3Y)10.29%
Maximum drawdown-16.55%

Management

Fund managerJitendra Tolani
Managing since1 Feb 2025

What it holds

SecurityWeight
Sun Pharmaceutical Industries Limited21.3%
Divi's Laboratories Limited10.3%
Cipla Limited8.4%
Torrent Pharmaceuticals Limited7.6%
Laurus Labs Limited7.1%
Dr. Reddy's Laboratories Limited7.1%
Lupin Limited5.9%
Aurobindo Pharma Limited4.4%
Alkem Laboratories Limited3.4%
Glenmark Pharmaceuticals Limited3.4%
SectorWeight
Pharmaceuticals & Biotechnology99.8%

Portfolio disclosed: 99.8% by weight.

Related

Source: the OmniAsset signed reference snapshot, as of 4 Sep 2026. Figures are deterministic; missing data is withheld, never estimated. See methodology and data sources. Not investment advice.

Research this fund and compare it — on your device.

Get OmniAsset on Google Play The mutual fund tracker